Protagonist aborts lead ulcerative colitis program after drug fizzles in PhIIb, stock craters
The lead therapy at Protagonist has flunked a mid-stage trial, pushing the Newark-based company to pull the plug on its ulcerative colitis drug PTG-100. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.